You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Brentuximab vedotin

Showing 26 - 50 of 296
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Lymphoma
  • Brentuximab Vedotin
  • +3 more
  • Beijing, China
  • +15 more
Jan 4, 2023

ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)

Terminated
  • ALK+ Anaplastic Large Cell Lymphoma
  • Wien, Austria
    Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
Feb 15, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Saint Louis, Columbus (Brentuximab vedotin, Lenalidomide)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Saint Louis, Missouri
  • +1 more
Feb 16, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

Completed
  • Lymphatic Diseases
  • Brentuximab Vedotin
  • Bologna, Italy
  • +3 more
Mar 21, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc Trial in Canada, United States (Brentuximab Vedotin, Placebo)

Recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • +2 more
  • Brentuximab Vedotin
  • Placebo
  • Los Angeles, California
  • +9 more
May 12, 2022

CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker

Recruiting
  • CD30-Positive Neoplastic Cells Present
  • Malignant Mesothelioma
  • Brentuximab Vedotin
  • Laboratory Biomarker Analysis
  • Houston, Texas
    M D Anderson Cancer Center
Jan 3, 2022

Diffuse Cutaneous Systemic Sclerosis Trial in London (Brentuximab Vedotin)

Recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • Brentuximab Vedotin
  • London, Ontario, Canada
    Rheumatology Clinic, St. Joseph's Health Care
Feb 3, 2022

Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

Recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin 50 MG [Adcetris]
  • Leon, Guanajuato, Mexico
    Hospital Regional Alta Especialidad Bajio
Oct 24, 2022

Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab

Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Dec 17, 2021

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

Not yet recruiting
  • NK/T Cell Lymphoma Nos
  • Brentuximab Vedotin in Combination with Tislelizumab
  • (no location specified)
Apr 6, 2022

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

Hodgkin Disease Trial in Worldwide (Brentuximab vedotin, Doxorubicin, Vinblastine)

Completed
Has Results
  • Hodgkin Disease
  • Brentuximab vedotin
  • +3 more
  • Aurora, Colorado
  • +13 more
Jun 17, 2022

Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United

Active, not recruiting
Has Results
  • Ann Arbor Stage IB Hodgkin Lymphoma
  • +10 more
  • Brentuximab Vedotin
  • Nivolumab
  • Palo Alto, California
  • +8 more
Jul 20, 2022

Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,

Active, not recruiting
  • Classic Hodgkin Lymphoma
  • +2 more
  • Brentuximab Vedotin
  • +2 more
  • Duarte, California
  • +5 more
Mar 17, 2022

Hodgkin Lymphoma, Adult Trial in United States (Brentuximab vedotin, ABVD)

Completed
Has Results
  • Hodgkin Lymphoma, Adult
  • Brentuximab vedotin
  • ABVD
  • Duarte, California
  • +5 more
Nov 8, 2021

Hodgkin Lymphoma Trial in United Kingdom (Involved site radiotherapy, Doxorubicin, Bleomycin)

Recruiting
  • Hodgkin Lymphoma
  • Involved site radiotherapy
  • +6 more
  • Aberdeen, United Kingdom
  • +6 more
May 24, 2022

Advanced Classical Hodgkin's Lymphoma in Brazil Treated With

Not yet recruiting
  • Hodgkin Lymphoma
  • No Intervention
  • Salvador, Bahia, Brazil
  • +5 more
Oct 23, 2023

Melanoma, NSCLC Trial in United States (brentuximab vedotin, pembrolizumab)

Recruiting
  • Melanoma
  • +2 more
  • Tucson, Arizona
  • +31 more
Jan 20, 2023

Classical Hodgkin Lymphoma Trial in Charlottesville (Pembrolizumab, Doxorubicin, Vinblastine)

Recruiting
  • Classical Hodgkin Lymphoma
  • Charlottesville, Virginia
    University of Virginia
Jul 27, 2022

Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Caba (Evaluation of

Recruiting
  • Hodgkin Lymphoma, Adult
  • +2 more
  • Evaluation of therapeutical approach after ASCT
  • Caba, Argentina
    FUNDALEU
Oct 1, 2021

Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma
  • B-MAD chemotherapy
  • Bangkok, Thailand
    King Chulalongkorn Memorial Hospital
May 7, 2022

Lymphoma, T-Cell, Peripheral Trial in Czechia (Adcetris 50 MG Injection, Endoxan, Doxorubicin)

Not yet recruiting
  • Lymphoma, T-Cell, Peripheral
  • Adcetris 50 MG Injection
  • +4 more
  • Brno, Czechia
  • +6 more
Aug 26, 2021